StrideBio is a product-driven, fully integrated gene therapy company focused on creating and developing innovative genetic medicines with life-changing or curative potential for patients with devastating conditions, including monogenic rare disease and beyond.
We leverage our proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Improved characteristics of StrideBio’s AAV vectors include evasion of pre-existing neutralizing antibodies, tissue targeting and de-targeting, enhanced potency, and manufacturability at scale. Combined with our gene construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency.
StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C, which houses our offices, research labs and in-house AAV manufacturing facilities.
We leverage our proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Improved characteristics of StrideBio’s AAV vectors include evasion of pre-existing neutralizing antibodies, tissue targeting and de-targeting, enhanced potency, and manufacturability at scale. Combined with our gene construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency.
StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C, which houses our offices, research labs and in-house AAV manufacturing facilities.
Location: United States, North Carolina, Durham
Employees: 51-200
Total raised: $97.2M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| - | UCB Ventur... | ucbventure... |
| - | Octagon Ca... | octagoninv... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.03.2021 | Series B | $81.5M | - |
| 14.06.2018 | Series A | $15.7M | - |
Mentions in press and media 13
| Date | Title | Description |
| 16.03.2021 | StrideBio Closes $81.5M Series B Financing | StrideBio, Inc., a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies, closed a $81.5m Series B funding round. The round was co-led by Northpond Ventures and Novo Holdings A/S ... |
| 16.03.2021 | StrideBio Announces Closing of $81.5M Series B Financing | |
| 16.03.2021 | StrideBio Raises $81.5M Series B Round | RESEARCH TRIANGLE PARK, NC, StrideBio today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million. >> Click here for more funding data on StrideBio >> To export StrideBio funding data ... |
| 16.03.2021 | StrideBio Announces Closing of $81.5M Series B Financing | RESEARCH TRIANGLE PARK, N.C., March 16, 2021 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round... |
| 16.03.2021 | StrideBio Announces Closing of $81.5M Series B Financing | Research Triangle Park, N.C., Mar. 16, 2021 – StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised ... |
| 03.01.2019 | Hatteras Venture Partners-backed StrideBio Appoints Sapan Shah as CEO | StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, announced today that the Board of Directors has appointed Sapan Shah, Ph.D. as Chief Executive Officer and a member of the company’s board. Dr S... |
| 03.01.2019 | Hatteras Venture Partners-backed StrideBio Appoints Sapan Shah as CEO | StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, announced today that the Board of Directors has appointed Sapan Shah, Ph.D. as Chief Executive Officer and a member of the company’s board. Dr S... |
| 14.06.2018 | Term Sheet — Thursday, June 14 | 5 Qs WITH A DEALMAKER You probably haven’t heard of Fleetcor Technologies. Paid Content How can you protect what you can't see? From ExtraHop But what is quite interesting is Fleetcor’s acquisition strategy. Since the company’s inception in... |
| 14.06.2018 | StrideBio Raises $15.7M Series A | StrideBio, Inc, a US-based company developing novel AAV vectors for in vivo gene therapies announced today that it had closed an oversubscribed Series A Financing Round of $15.7 million. The financing was led by Hatteras Venture Partners. C... |
| 13.06.2018 | StrideBio Closes $15.7M in Series A Financing | StrideBio, Inc., a Durham, NC-based company developing novel AAV vectors for in vivo gene therapies, closed a Series A Financing Round of $15.7m. The round was led by Hatteras Venture Partners with participation from Takeda Ventures, UCB Ve... |
Show more